Special Issue "Disease and the Hippo Pathway: Cellular and Molecular Mechanisms"

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell Signaling and Regulated Cell Death".

Deadline for manuscript submissions: closed (31 March 2019)

Special Issue Editor

Guest Editor
Dr. Carsten Gram Hansen

Medical Research Council Centre for Inflammation Research, University of Edinburgh, United Kingdom
Website | E-Mail
Interests: YAP/TAZ; Hippo pathway; mechanotransduction; inflammation; Caveolae; cell dynamics; cancer and stem cells

Special Issue Information

Dear Colleagues,

The Hippo pathway is a highly dynamic cellular signaling nexus, integrating mechanotransduction, cell polarity, inflammation, and numerous types of paracrine signaling. The Hippo pathway plays central roles in multiple cell types and regulates regeneration, metabolism and development. If not tightly regulated, dysregulated Hippo pathway signaling drives the onset and progression of a range of diseases, including fibrosis and cancer. The molecular understanding of the Hippo pathway is rapidly evolving, emphasized by the relative recent seminal discovery of the LATS1/2 mediated, but Hippo independent, kinase regulation of YAP/TAZ via the MAP4K family. The aim of this Special Issue is to provide an overview of how a dysregulated Hippo pathway is a common driver of specific diseases, with a particular focus on the underlying molecular and cellular mechanisms that causes the Hippo pathway to go awry, and how this drives disease. We particularly welcome contributions, in the form of either original research articles or concise reviews, with mechanistic and functional insights into either specific diseases or common pathological phenomena caused by Hippo pathway dysregulation.

We hope that the articles will analyse disease-specific, as well as common themes, which will provide valuable insights into the fundamental molecular mechanisms in the dysfunctioning Hippo pathway, and thereby offer practical insights into potential future therapeutic intervention strategies.

Dr. Carsten Gram Hansen
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Hippo pathway
  • YAP/TAZ
  • disease mechanism
  • mechanotransduction
  • GPCR
  • inflammation
  • regeneration

Published Papers (1 paper)

View options order results:
result details:
Displaying articles 1-1
Export citation of selected articles as:

Review

Open AccessReview The Hippo Pathway in Prostate Cancer
Cells 2019, 8(4), 370; https://doi.org/10.3390/cells8040370 (registering DOI)
Received: 19 March 2019 / Revised: 17 April 2019 / Accepted: 19 April 2019 / Published: 23 April 2019
PDF Full-text (8199 KB)
Abstract
Despite recent efforts, prostate cancer (PCa) remains one of the most common cancers in men. Currently, there is no effective treatment for castration-resistant prostate cancer (CRPC). There is, therefore, an urgent need to identify new therapeutic targets. The Hippo pathway and its downstream [...] Read more.
Despite recent efforts, prostate cancer (PCa) remains one of the most common cancers in men. Currently, there is no effective treatment for castration-resistant prostate cancer (CRPC). There is, therefore, an urgent need to identify new therapeutic targets. The Hippo pathway and its downstream effectors—the transcriptional co-activators, Yes-associated protein (YAP) and its paralog, transcriptional co-activator with PDZ-binding motif (TAZ)—are foremost regulators of stem cells and cancer biology. Defective Hippo pathway signaling and YAP/TAZ hyperactivation are common across various cancers. Here, we draw on insights learned from other types of cancers and review the latest advances linking the Hippo pathway and YAP/TAZ to PCa onset and progression. We examine the regulatory interaction between Hippo-YAP/TAZ and the androgen receptor (AR), as main regulators of PCa development, and how uncontrolled expression of YAP/TAZ drives castration resistance by inducing cellular stemness. Finally, we survey the potential therapeutic targeting of the Hippo pathway and YAP/TAZ to overcome PCa. Full article
(This article belongs to the Special Issue Disease and the Hippo Pathway: Cellular and Molecular Mechanisms)
Cells EISSN 2073-4409 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top